Escape mechanisms from antibody therapy to lymphoma cells: Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation
- 4 December 2009
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 390 (1), 48-53
- https://doi.org/10.1016/j.bbrc.2009.09.059
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Biomedical Innovation (20591116)
- Ministry of Health, Labour and Welfare
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 27 references indexed in Scilit:
- Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significanceBlood, 2009
- Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximabInternational Journal of Hematology, 2009
- Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's LymphomaNew England Journal of Medicine, 2008
- Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both GlobalCD20Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional LevelsClinical Cancer Research, 2008
- Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing ChemotherapyInternational Journal of Hematology, 2007
- Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.Haematologica, 2007
- Monoclonal Antibody Therapy for B-Cell MalignanciesSeminars in Oncology, 2006
- Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemiaBlood, 2003
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002